The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Aurinia Pharmaceuticals Pretax Margin % Related Terms
Aurinia Pharmaceuticals Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AUPH vs KOD, ABCL, AGIO: Pretax Margin % Comparison
For the Biotechnology subindustry, Aurinia Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurinia Pharmaceuticals Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Aurinia Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurinia Pharmaceuticals (AUPH) has a Pretax Margin % of 56.53% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Aurinia Pharmaceuticals and its competitors. According to the industry distribution chart, Aurinia Pharmaceuticals ranks #58 out of 944 companies in the Biotechnology industry, placing it in the top 6.1%.
Is Aurinia Pharmaceuticals' Pretax Margin % too high?
Aurinia Pharmaceuticals' current Pretax Margin % is 56.53%. Based on the distribution chart, Aurinia Pharmaceuticals ranks #58 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aurinia Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' Pretax Margin % compare to KOD and ABCL?
According to the Biotechnology industry distribution chart, Aurinia Pharmaceuticals ranks #58 out of 944 companies for Pretax Margin %. This places Aurinia Pharmaceuticals in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Aurinia Pharmaceuticals and its competitors. Aurinia Pharmaceuticals's current Pretax Margin % is 56.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (AUPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $13.97, compared to a current price of $16.78 — trading 20.1% above its estimated fair value. The current Pretax Margin % is 56.53%. Aurinia Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Aurinia Pharmaceuticals (AUPH), the current Pretax Margin % is 56.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurinia Pharmaceuticals (AUPH) Overvalued in 2026?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued.
The current stock price of $16.78 is trading 20.1% above its estimated GF Value™ of $13.97.
GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for AUPH:
Pretax Margin %: 56.53%
GF Value™: $13.97 vs. price of $16.78 (20.1% above fair value)
No single metric tells the full story. See the AUPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
82GF Score
Get the complete analysis for AUPH
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AUPH has been successfully added to your 
